New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents.
Laurent Roberto ChiarelliMatteo MoriGiangiacomo BerettaArianna GelainElena PiniJose Camilla SammartinoGiovanni StelitanoDaniela BarloccoLuca CostantinoMargherita LapilloGiulio PoliIsabella CaligiuriFlavio RizzolioMarco BellinzoniTiziano TuccinardiStefania VillaFiorella MeneghettiPublished in: Journal of enzyme inhibition and medicinal chemistry (2019)
Starting from the analysis of the hypothetical binding mode of our previous furan-based hit (I), we successfully achieved our objective to replace the nitro moiety, leading to the disclosure of a new lead exhibiting a strong activity against MbtI. Our best candidate 1 h displayed a Ki of 8.8 µM and its antimycobacterial activity (MIC99 = 250 µM) is conceivably related to mycobactin biosynthesis inhibition. These results support the hypothesis that 5-phenylfuran-2-carboxylic derivatives are a promising class of MbtI inhibitors.